Kokando’s Contract Drug Manufacturing
Our contract drug manufacturing system
We contribute to contractors’ business by working closely with them
The amended Pharmaceutical Affairs Law allows pharmaceutical companies which do not own manufacturing facilities to obtain marketing approvals of pharmaceutical products. More than ever, manufacturing pharmaceutical products requires expertise. Toward the future, contract manufacturing in close partnership with contract givers, enhancing strengths each of the contract givers has, and searching for efficiency are the keys to successfully manufacturing pharmaceutical products.
For producers and distributors searching for an OEM
Taking advantage of GMP certified plants and of the integrative production system from development to manufacturing to quality management, we accept contract manufacturing for ethical drugs, OTC drugs, and investigational drugs. As to ethical drugs specifically, we have received orders for tablets and granules from numerous pharmaceutical companies. EU-GMP-certified, we are capable accepting contract manufacturing of products intended for the EU markets. The brand-new Kureha plant, which has gone into full operation in 2010, is equipped with hardware that meets trilateral GMP requirements, namely, EU-GMP, C-GMP, and J-GMP.
With our thorough quality control system and the system that allows on-time product delivery, Kokando will work to our contract givers’ advantage. We eagerly look forward to opportunities to serve you through contract manufacturing.
Our features pharmaceutical technologies
In addition to tablets in general, we have technology for complete manufacturing of oval tablets, film-coated tablets, double-layer tablets, dry-coated tablets, orally-disintegrating tablets, sugar-coated tablets, and pills. We have accumulated rich knowledge technological base of liquid and solid dosage forms using Japanese Chinese medicine.
Kokando’s OEM system
Solid dosage products such as tablets, pills, granules and powders are manufactured at the Headquarters Plant, and liquid dosage form at the Namerikawa Plant.
In addition, the new Kureha plant, located in Southern Kureha Industrial Park, has gone into full operation in September 2010. The plant has 4 production lines, has a capacity of producing 4 billion tablets per year, and is specializing in solid dosage forms. This state-of-the-art plant is environmentally friendly, energy- and labor-efficient, and cost effective.